Trials / Withdrawn
WithdrawnNCT00143429
Corneal Versus Conjunctival Delivery Using a Delivery Device
Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Compare the antihypertensive efficacy of three methods for installing Xalatan
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xalatan |
Timeline
- First posted
- 2005-09-02
- Last updated
- 2021-02-02
Source: ClinicalTrials.gov record NCT00143429. Inclusion in this directory is not an endorsement.